0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover0.00%IV-176.75%PremiumMay 16, 2025Expiry Date9.58Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.61Leverage Ratio--Theta--Rho--Eff Leverage--Vega
MeiraGTx Holdings Stock Discussion
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
Benzinga· 2 mins ago
This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease
- RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with th...
shorts don't want any of this, i guess 😈
consolidation needs to hurry up and end at the old resistance.
Usually 500k volume stock. so it shouldn't take too long😉
no service revenue to 33.3 million in profits of service revenue 🥳
$11.00 here we come breaking 2 year resistance . major news!
No comment yet